AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15334791
Drug: Glimepiride and
RxNorm normalized name: glimepiride and pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride and Metformin
Trial: 26367325
Drug: Interdisciplinary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary therapy (4 weekly exercise sessions, 1 weekly group therapy session, 1 weekly nutritional education session)
Trial: 26367325
Drug: Interdisciplinary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary therapy
Trial: 24425846
Drug: No PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PRP gel (Control)
Trial: 10192750
Drug: Mibefradil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (50 mg once daily for 1 week)
Trial: 2182945
Drug: Diethylstilbestrol diphosphate
RxNorm normalized name: Diethylstilbestrol Diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol diphosphate (DES‐DP) plus vindesine (VND) 3 mg/m2 intravenously on days 8, 15, and 22 (group B)
Trial: 29504499
Drug: Quadrupling inhaled
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrupling inhaled glucocorticoids (increase by a factor of 4)
Trial: 29504499
Drug: Non-quadrupling group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-quadrupling group (same self-management plan without dose increase)
Trial: 29504499
Drug: Quadrupling inhaled
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrupling inhaled glucocorticoids
Trial: 27041524
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for 28 weeks
Trial: 24450858
Drug: Idelalisib, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib, 150 mg twice daily
Trial: 18198305
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet (LCD, 890 kcal/d supplement diet until 15% weight loss, then weight maintenance)
Trial: 7664860
Drug: Oral flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral flurbiprofen alone
Trial: 2651176
Drug: Bacampicillin suspension,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin suspension, given twice daily, 40 mg/kg body weight for 10 days
Trial: 2651176
Drug: Amoxycillin suspension,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin suspension, given three times daily, 40 mg/kg body weight for 10 days
Trial: 12891310
Drug: Ramipril (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (starting dose 2.5 mg in group 1 and 5 mg in group 2, increased to 10 mg daily over 8 weeks)
Trial: 12891310
Drug: Ramipril (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (group 1: gradual regimen starting at 2.5 mg; group 2: more active regimen starting at 5 mg)
Trial: 10472219
Drug: Metoclopramide 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.15 mg kg‐1 i.v.
Trial: 1670442
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with no immediate injection of enoxaparin (Group I, 65 patients)
Trial: 1670442
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with 20 mg of enoxaparin one hour after the onset of anaesthesia (Group II, 61 patients)
Trial: 28319467
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 1 g
Trial: 9602870
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcipotriol and betamethasone valerate after 2 weeks of calcipotriol monotherapy
Trial: 7997001
Drug: Day-care treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-care treatment
Trial: 22325733
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (active control)
Trial: 30523659
Drug: Hybrid intervention
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid intervention combining exergaming and physical therapy, 90 minutes twice a week for 12 weeks
Trial: 23614897
Drug: FM containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FM containing 10(6) cfu LG2055/g
Trial: 23614897
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 cfu LG2055/g)
Trial: 14670810
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg orally 4 times daily)
Trial: 17688720
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous fluid (group 1)
Trial: 11578293
Drug: Intravenous crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous crystalloid based on body-weight (group 2)
Trial: 9631990
Drug: Fluconazole 300
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 300 mg
Trial: 2146875
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (2 g/kg/month)
Trial: 21329776
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) vaccination (2 μg/dose)
Trial: 21329776
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) vaccination (10 μg/dose)
Trial: 11101487
Drug: Fructooligosaccharides (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructooligosaccharides (20 g powder/d)
Trial: 21484237
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of dexamethasone (DEX)
Trial: 8832535
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of hydrocortisone (HCO)
Trial: 30572837
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg tramadol
Trial: 24931567
Drug: MSDC-0160 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSDC-0160 (150 mg once daily)
Trial: 22818063
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg (T20 mg)
Trial: 22818063
Drug: Tadalafil 40
RxNorm normalized name: tadalafil 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 40 mg (T40 mg)
Trial: 17311545
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GH replacement therapy)
Trial: 1643912
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation challenge (MIC)
Trial: 1194144
Drug: Inspiratory elastic
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory elastic load (12.1 cmH2O/l)
Trial: 31363878
Drug: CCTA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCTA with iodixanol (270 mg I/mL), scanned with 100 kV, reconstruction by AIDR
Trial: 31363878
Drug: CCTA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCTA with iopromide (370 mg I/mL), scanned with 120 kV, reconstruction by filtered back projection
Trial: 15228830
Drug: Somatostatin analogue
RxNorm normalized name: Somatostatin analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analogue (Sandostatin 300 microgram subcutaneously/day in three divided doses)
Trial: 15228830
Drug: Conventional methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional methods (nil per orum, total parenteral nutrition, antibiotics, skin and wound care, control of sepsis)
Trial: 11097669
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with 1 mg morphine
Trial: 8477148
Drug: l-alpha-glyceryl-phosphorylcholine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-alpha-glyceryl-phosphorylcholine (alpha GPC)
Trial: 8477148
Drug: ST200 (acetyl-l-carnitine)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST200 (acetyl-l-carnitine)
Trial: 2948256
Drug: Pindolol (2.5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (2.5-7.5 mg, administered gradually by mouth)
Trial: 18197911
Drug: NT-proBNP level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP level >or=2220 pg/mL
Trial: 10072664
Drug: Mosapramine addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapramine addition to neuroleptic treatment
Trial: 1790543
Drug: Topilene (generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topilene (generic formulation) cream
Trial: 1790543
Drug: Diprolene (innovator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprolene (innovator formulation) cream
Trial: 28495411
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied intraorally and extraorally with a 660-nm and 810-nm laser, respectively, at 200 mW for 10 seconds, 2 J, 1.5 J/cm2 and 7 J/cm2, repeated 2 times per week for 3 weeks.
Trial: 28495411
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side received laser simulation instead of actual laser therapy.
Trial: 21748445
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration (group A)
Trial: 19487639
Drug: Weekly incontinence
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly incontinence
Trial: 7953032
Drug: Daily Living
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Living Programme (DLP)
Trial: 7714303
Drug: Nortriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (75 mg/day)
Trial: 2649118
Drug: Haloperidol 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 0.05 mg/kg/day
Trial: 2649118
Drug: Haloperidol 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 0.025 mg/kg/day
Trial: 27029707
Drug: Tailored high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored high-dose oral vitamin D supplementation (T)
Trial: 27029707
Drug: Tailored high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored high-dose oral vitamin D supplementation (T) after switching from C
Trial: 25212095
Drug: Caffeinated energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated energy drink (3 mg caffeine/kg body mass)
Trial: 25212095
Drug: Placebo energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo energy drink (0 mg caffeine/kg body mass)
Trial: 22370839
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus casei and Bifidobacterium breve), administered three times a day for an average treatment duration of 5.06±2.18 days
Trial: 22370839
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered three times a day for an average treatment duration of 5.49±3.17 days
Trial: 18269776
Drug: Pemetrexed 400‐600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 400‐600 mg/m2 and epirubicin 60‐90 mg/m2
Trial: 12091596
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times weekly subcutaneous epoetin beta treatment
Trial: 7901636
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (2.4 mg retinol) and iron (60 mg elemental iron)
Trial: 2832202
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (before treatment)
Trial: 27813716
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied on the right side (diode laser 660 nm, 40 mW, 1 min, 2.4 J of total energy)
Trial: 27813716
Drug: Nonirradiated mini-implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonirradiated mini-implants (control group)
Trial: 24023757
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin for 3.2 years
Trial: 12925453
Drug: CYP3A4-MET statin
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP3A4-MET statin (atorvastatin, lovastatin, simvastatin, cerivastatin) with clopidogrel
Trial: 30251616
Drug: Individual placement
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual placement and support (IPS) for 6 months in addition to treatment as usual (TAU)
Trial: 29074815
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Care + Hyperbaric Oxygen Therapy (SC+HBOT)
Trial: 24818336
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 200,000 IU ulinastatin in 100 mL of 0.9% saline given over one hour every 12 hours for 5 days
Trial: 24818336
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 200,000 IU ulinastatin
Trial: 9506875
Drug: Meloxicam 15
RxNorm normalized name: meloxicam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 15 mg
Trial: 19151299
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of meloxicam and gabapentin
Trial: 17986361
Drug: Clinical pathway
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pathway (appropriate use of practice guidelines, supplies of drugs and ancillary services, new organization and procedures, patient education)
Trial: 17701882
Drug: Cerivastatin 0.4
RxNorm normalized name: cerivastatin 0.4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.4 mg daily for 12 weeks
Trial: 11354394
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% 3 times daily
Trial: 7955995
Drug: CS-045 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-045 (400 mg daily)
Trial: 20854930
Drug: Sertraline+tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline+tDCS
Trial: 17212098
Drug: Weekly hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly hepatic arterial infusion (HAI) chemotherapy with 5-FU (1500 mg) for 8 weeks
Trial: 17212098
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion group with identical total dosage of 5-FU
Trial: 17212098
Drug: Weekly HAI
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly HAI chemotherapy
Trial: 17212098
Drug: HAI chemotherapy
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI chemotherapy using a W spiral catheter
Trial: 22260337
Drug: Nabilone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (6 mg)
Trial: 22260337
Drug: Nabilone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (4 mg), Nabilone (6 mg), Nabilone (8 mg)
Trial: 10650898
Drug: Dolasetron plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron plus dexamethasone (100 mg dolasetron i.v. + 20 mg dexamethasone)
Trial: 10650898
Drug: Dolasetron alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron alone (100 mg dolasetron i.v.)
Trial: 27882007
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 on d1) and Cisplatin (25 mg/m2 on d1-3)
Trial: 27882007
Drug: Cisplatin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (25 mg/m2 on d1-3) and Fluorouracil (400 mg/m2)
Trial: 18931202
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) - 10 mg/kg IV bolus after induction followed by 1 mg/kg/hr maintenance infusion
Trial: 12185445
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (200 mg/ml)
Trial: 8938880
Drug: Levocabastine nasal
RxNorm normalized name: levocabastine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine nasal spray (0.5 mg/ml)
Trial: 1769132
Drug: Fenfluramine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (60 mg orally) + naloxone (3 mg/h infusion over 5 hours)
Trial: 3987071
Drug: Fenfluramine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (60 mg orally)
Trial: 30196900
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g aspartame (placebo)
Trial: 23516864
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of phospholipid nanoparticles
Trial: 22851566
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m(2) every 3 weeks for four cycles (P3)
Trial: 17655758
Drug: Guideline-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based treatment by occupational physicians (OPs)
Trial: 25527036
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g glucose post-learning
Trial: 23682073
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day folic acid supplement
Trial: 23682073
Drug: Control (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment without folic acid)
Trial: 19159632
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (ascorbic acid) 3 g
Trial: 17317022
Drug: Levothyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L-T4) treatment after 7 weeks
Trial: 15632894
Drug: Rosuvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin therapy without compliance-enhancing program
Trial: 9625576
Drug: Fludarabine, cytarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine, cytarabine, and G-CSF (FLAG)
Trial: 7876398
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sparfloxacin
Trial: 7876398
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sparfloxacin
Trial: 7876398
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg sparfloxacin
Trial: 3247592
Drug: Ranitidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administered at 1815 h
Trial: 3247592
Drug: Ranitidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administered at 2200 h
Trial: 30145306
Drug: Cognitive Working
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Working Memory Training (CWMT) with medication
Trial: 18294251
Drug: Almotriptan (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan (12.5 mg) administered when pain intensity was mild (within 1 h of headache onset)
Trial: 18294251
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered when pain intensity was moderate/severe
Trial: 11514117
Drug: Kava extract
RxNorm normalized name: Kava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kava extract with hormone replacement therapy